ライフサイエンスコーパス: PET scan

1 received a 90-min dynamic (S)-(18)F-THK5117 PET scan.

2 83 and micro-CT scan, but not with (18)F-FDG PET scan.

3 and additionally an experimental (11)C-PE2I PET scan.

4 ximab vedotin treatment, patients received a PET scan.

5 ity and underwent a second [(18)F]fallypride PET scan.

6 -FDG was injected, followed by a 3-h dynamic PET scan.

7 ch would expectedly yield a negative amyloid PET scan.

8 administration of SB-269970 before a second PET scan.

9 ity and underwent a second [(18)F]fallypride PET scan.

10 f the diaphragm were acquired throughout the PET scan.

11 14 MBq (mean +/- SD) of (11)C-PBR28 for each PET scan.

12 y)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide PET scan.

13 hologic (astrocytosis) aspects from a single PET scan.

14 dication of a clinically justified (18)F-FDG PET scan.

15 h, and FTD patients also underwent (18)F-FDG PET scans.

16 h each undergoing three 90-min (11)C-HOMADAM PET scans.

17 r optimal visual interpretation of (11)C-PIB PET scans.

18 All patients had positive PIB-PET scans.

19 ilateral motor symptoms underwent (18)F-DTBZ PET scans.

20 s well as magnetic resonance imaging and PiB-PET scans.

21 rcellations were applied to the coregistered PET scans.

22 camera was used to track head motion during PET scans.

23 luid Abeta1-42 biomarker data but no amyloid PET scans.

24 Tissue uptake was extracted from whole-body PET scans.

25 (11)C](R)PK11195, [(18)F]FDG, and [(11)C]PIB PET scans.

26 iple organs on the CT scan and copied to the PET scans.

27 tching healthy controls received (11)C-PBR28 PET scans.

28 and therefore diagnostic accuracy of cardiac PET scans.

29 )Tc-based hepatobiliary scans, and (18)F-FDG PET scans.

30 ria or (for MP) by changes in (123)I-MIBG or PET scans.

31 seline amyloid positron emission tomography (PET) scan.

32 oxyglucose positron emission tomography (FDG-PET) scans.

33 yglucose (FDG) positron emission tomography (PET) scans.

34 ived three cycles of ABVD and then underwent PET scanning.

35 ) were recruited, and 571 patients underwent PET scanning.

36 cancer with limited evidence on the role of PET scanning.

37 and cigarette smoking underwent [(18)F]-DOPA PET scanning.

38 A subjects showed beta-amyloid deposition on PET scanning.

39 )C]carfentanil positron emission tomography (PET) scanning.

40 ic CT scan (80 kV, 165 mAs) and a subsequent PET scan (2 min per bed position).

41 PET scan (5 patients) or SPECT (2 patients) revealed par

42 dar followed by another (R)-[(11)C]verapamil PET scan 60 min later.

43 patients had a follow-up (11)C-(R)-rolipram PET scan 8 weeks after treatment with an SSRI.

44 patients had a follow-up (11)C-(R)-rolipram PET scan ~8 weeks after treatment with an SSRI.

45 abolic RSN expression in cerebral blood flow PET scans acquired at rest and during task performance.

46 view, followed by a series of 13 whole-body PET scans acquired over a 90-min period.

47 of each other (501 participants had a second PET scan after 2 years, including 150 participants with

48 n; median age, 37 y) each underwent a 90-min PET scan after an intravenous injection of (18)F-GE-179.

49 vival in patients attaining a negative early PET scan after two cycles of ABVD (doxorubicin, bleomyci

50 An early PET scan after two cycles of treatment can effectively p

51 0 patients (62.5%) presented with a negative PET scan after two cycles of treatment.

52 patients (>/=90%) achieved negative interim PET scans after 2 and 4 cycles of BV + AVD.

53 en and 3 women, underwent whole-body dynamic PET scans after bolus injection of (11)C-DPA-713.

54 ans before and after chemotherapy as well as PET scans after chemotherapy.

55 hereafter referred to as simply florbetapir)-PET scan and at least 1 CSF beta-amyloid 1-42 (Abeta1-42

56 younger, more likely to have a positive PiB-PET scan and carry at least one apolipoprotein E varepsi

57 ers underwent a high-resolution [(18)F]FEPPA PET scan and MRI.

58 ers underwent a high-resolution [(18)F]FEPPA PET scan and MRI.

59 xenografts were detected by micro CT, (18)F-PET scan and NIR imaging scan.

60 antification is achieved by a 60-min dynamic PET scan and the use of either cerebellum or midbrain as

61 o had a baseline Pittsburgh Compound B (PiB) PET scan and two 3T MRI scans ~18-months apart.

62 he patients could tolerate the procedures of PET scanning and RT.

63 male volunteers (age, 18-40 y) with up to 3 PET scans and 3 subjects per dose level.

64 ke value ratios (SUVRs) were calculated from PET scans and a mean global cortical SUVR was calculated

65 Data obtained from PET scans and biodistribution studies were extrapolated

66 (18)F-FET PET scans and ex vivo autoradiography were performed in

67 FDG-PET scans and helical CT scans were obtained before and

68 patients underwent dynamic (11)C-(R)PK11195 PET scans and perfusion MR imaging acquisition.

69 FDG-PET scans and pulmonary artery acceleration times were o

70 ed these VOIs to the corresponding (18)F-FET PET scans and PWI maps.

71 n 3 cohorts; all underwent dynamic (18)F-FDG PET scans and serial pharmacokinetic sampling at baselin

72 lowed for more than 2 y by regular (18)F-FDG PET scans and specific AE serology, 11 (25%) presented p

73 ers of bone lesions on CT, FDG PET, and FDHT PET scans and the intensity of FDHT uptake are significa

74 ncer patients underwent diagnostic (18)F-FDG PET scans and were tested for genetic mutations.

75 ncer patients underwent diagnostic (18)F-FDG PET scans and were tested for genetic mutations.

76 r, we utilized positron emission tomography (PET) scanning and the tracer (18)F-fluorodeoxyglucose (F

77 percent of patients had a positive (18)F-FLT PET scan, and 49% had (18)F-FDG PET-positive foci.

78 in epsilon4, concurrent fludeoxyglucose F 18 PET scan, and baseline cognitive status.

79 were perfused and sacrificed after the final PET scan, and radioactivity in dissected tissues was mea

80 linic Study of Aging who completed a 3T MRI, PET scans, and APOE genotype, and had lifestyle activity

81 During all PET scans, arterial blood was monitored continuously.

82 ts from group 2, who underwent a second PSMA PET scan as a follow-up, were evaluated to determine the

83 amol have used visual assessment to classify PET scans as negative or positive for brain amyloid.

84 ocols using (18)F-DCFPyL (n = 62, 269.8 MBq, PET scan at 120 min after injection) or (68)Ga-PSMA-HBED

85 ocols using (18)F-DCFPyL (n = 62, 269.8 MBq, PET scan at 120 min after injection) or (68)Ga-PSMA-HBED

86 nt at magnetic resonance imaging, a positive PET scan at baseline, or lack of improvement at repeat P

87 genic strain were imaged with 60-min dynamic PET scans at 7-9, 12, 15, and 18-22 mo of age.

88 Patients underwent (89)Zr-bevacizumab PET scans at baseline and 2 and 6 wk after initiating ei

89 were subjected to 5 min of static whole-body PET scans at different time points after intravenous inj

90 ic innervation) were calculated from dynamic PET scans at the location of BAT and WAT.

91 fraction (OEF) were calculated from dynamic PET scans at the location of BAT, muscle, and white adip

92 ry 1, 1997, and December 31, 2011, and had a PET scan available for current review.

93 anced solid tumors underwent (11)C-erlotinib PET scans before and after a 1,000-mg dose of elacridar.

94 PET scans before and after task performance indicated a

95 erentiated NETs underwent (89)Zr-bevacizumab PET scans before and at 2 and 12 wk during everolimus tr

96 Rats were subjected to (11)C-PK11195 PET scans before SE; at 4 h after SE; at 1, 2, 5, 7, 14,

97 nteers (HV) underwent two [(11)C]carfentanil PET scans, before and after an oral administration of 0.

98 d of patients with MCC who underwent staging PET scanning between January 1997 and October 2010.

99 previously published criteria: "high" if the PET scan changed the primary treatment modality or inten

100 A positron emission tomography (PET) scan confirmed the lung lesion and the mediastinal

101 that an early positron emission tomography (PET) scan could be used to adapt treatment.

102 ved a negative positron emission tomography (PET) scan (Deauville score of 1-3) received 30 Gy ISRT.

103 PET/CT (PET scan duration 1 h) was performed 21-25 (day 1) and 4

104 n a series of pregnant women who underwent a PET scan during a clinical workup for malignancies.

105 tative stability assessment for simultaneous PET scanning during functional MRI studies was performed

106 In addition to an (18)F-FDG PET scan, each patient underwent a 45-min (18)F-fluoromi

107 onsidered for quantitative (18)F-florbetaben PET scans, especially in assessing patients with brain a

108 After PET scanning, Evans blue dye (EBD) was injected into ani

109 ged 65 y or older undergoing initial-staging PET scanning for bladder, ovarian, pancreatic, small cel

110 In patients with prior NaF PET scans for comparison, continuing current therapy was

111 rameters extracted from sequential (18)F-FDG PET scans for early tumor response prediction after 2 cy

112 tinely used in positron emission tomography (PET) scans for cancer diagnosis, staging, and monitoring

113 cer patients who underwent staging (18)F-FDG PET scans from 2002 to 2013 at the Peter MacCallum Cance

114 follow-up ( approximately 24 mo) florbetapir PET scans from 332 Abeta+ and Abeta- subjects participat

115 nding on the quantification of (18)F-DPA-714 PET scans from a cohort of healthy subjects.

116 was prospectively quantified in (15)O-water PET scans from a PD patient cohort comprised of a longit

117 itive or negative was derived by ranking the PET scans from the autopsy cohort based on their composi

118 ced stages of PD were recruited for 18F-DTBZ PET scans from the Movement Disorders Clinic in the Chan

119 y-five painful metastatic locations with FDG PET scans geographically corresponding to 40 treatment f

120 The use of (18)F-FDG PET scans had a great impact on patients and may play an

121 Restaging (18)F-FDG PET scans had a high impact in 24 of 53 cases (45%) and

122 Using PET scan in humans, we have recently found that 5-HT 1A

123 lations were based on a whole-body (18)F-FDG PET scan in which differently sized spheres were placed

124 r (11)C-labeled ligands, allowing for serial PET scanning in a single subject.

125 Very little is known about (18)F-FDG PET scanning in amyloidosis.

126 udies aimed at assessing the role of interim PET scanning in HL, were retrospectively included.

127 ale subjects each had two 120-min [11C]PBR28 PET scans in 1 d, before and after an LPS challenge.

128 ined baseline 6-[(18)F]fluoro-L-DOPA (FDOPA)-PET scans in 15 nonsmokers and 30 nicotine-dependent smo

129 and markers since 1987-1989 with florbetapir PET scans in 2011-2013.

130 We obtained 62 cardiac (11)C-HED PET scans in 39 patients (30 men and 9 women; mean age +

131 proposed at Deauville for reviewing interim PET scans in advanced Hodgkin lymphoma is accurate and r

132 subjects underwent 10 consecutive whole-body PET scans in approximately 77 min.

133 m (68)Ga-DOTA-E-[c(RGDfK)]2 using whole-body PET scans in humans.

134 PET scans in rhesus monkeys were obtained on a small-ani

135 d with (11)C, thus allowing for safe, serial PET scans in the same individuals.

136 11)C]palmitate positron emission tomography (PET) scans in a family of five carrying the Pro90Ser CD3

137 epileptiform discharges had an [(18)F]GE-179 PET scan, in a cross-sectional study.

138 C-RO6931643, and (11)C-RO6924963 to baboons, PET scans indicated good brain entry, rapid washout, and

139 ild cognitive impairment for whom an amyloid PET scan is appropriate; and finally, developing educati

140 We confirmed that (18)F-FDG PET scanning is a reliable tool for BMI assessment in HL

141 fication of subjects on the basis of amyloid PET scans is increasingly being used in research studies

142 Vascular uptake on PET scans is seen in some patients.

143 (89)Zr-bevacizumab accumulation assessed by PET scanning may help in the selection of patients with

144 In conclusion, (18)F-GE180 PET scans may be useful for longitudinal monitoring of n

145 valuation with positron emission tomography (PET) scan may improve selection of patients who need red

146 For dynamic PET scans, mice were anesthetized during the entire meas

147 tially be quantitated with static whole-body PET scans not requiring arterial blood sampling.

148 Healthy subjects underwent a first PET scan of 120-min duration with either (11)C-tariquida

149 (11)C-elacridar (n = 5) followed by a second PET scan of 60-min duration with (R)-(11)C-verapamil.

150 A small-animal PET scan of a rhesus monkey revealed moderate initial br

151 thy tissues were estimated on (68)Ga-DOTATOC PET scans of 11 meningioma patients and 12 HGG patients.

152 l PET scanner, 15 rats underwent (18)F-CPFPX PET scans of 120-min duration.

153 (18)F-FDG PET scans of 132 children and adolescents (age, 1-20 y)

154 Sixty-nine (18)F-FET PET scans of 48 children and adolescents (median age, 13

155 Furthermore, whole-body PET scans of 5 female piglets (age +/- SD, 44 +/- 3 d; w

156 Serial whole-body PET scans of 5 subjects with recently diagnosed thyroid

157 e-activity curves were assessed with dynamic PET scans of 6 healthy human volunteers.

158 Dynamic (11)C-phenytoin PET scans of 6 healthy volunteers with arterial sampling

159 lamus in the nontumoral hemisphere in 77 AMT PET scans of 66 patients (41 men, 25 women; mean age +/-

160 meters were estimated from dynamic (18)F-FDG PET scans of breast cancer patients and used to simulate

161 At baseline, we acquired respiratory-gated PET scans of inhaled NN to measure tidal strain from end

162 Papio anubis baboons underwent PET scans of the brain after intravenous injection of (1

163 Small-animal PET scans of the brain region of male Wistar Hannover ra

164 presented here suggest that future clinical PET scans of tumors should be acquired later than 30 min

165 Small-animal PET scans of Wistar rats revealed moderate initial brain

166 omography (CT)/positron emission tomography (PET) scan of the chest, abdomen, and pelvis showed hydro

167 le) underwent positron emission tomographic (PET) scanning of the brain with the radiotracer 2-FA fol

168 We performed PET scans on mRCC patients with (89)Zr-bevacizumab, a VE

169 men; 5 women) each underwent 2 dynamic brain PET scans on the same day, first at baseline and then wi

170 tobacco smokers had one set of [(11)C]FLB457 PET scans on the same day, one before and one at 2.5-3 h

171 [(11)C]ABP688 positron emission tomography (PET) scans on the same day-before and during intravenous

172 be SUVAUC derived from 2 consecutive static PET scans, one centered on a large blood-pool structure

173 story of alcoholism underwent two [(11)C]RAC PET scans: one while tasting beer, and one while tasting

174 rsus abnormal positron emission tomographic (PET) scan or carcinoembryonic antigen (CEA).

175 X, 12 healthy volunteers underwent a dynamic PET scan over 120 min.

176 Four different PET scans processing pipelines from 2 different laborato

177 If the FDG-PET scan remained positive, patients received 4 biweekly

178 % (27 or 29) of patients achieved a negative PET scan, respectively.

179 Positron emission tomography (PET) scan response at month 6 was used as the main evalu

180 monstrated a significant difference in OS by PET scan result among patients younger than 60 y and bet

181 Our analyses demonstrated that NaF PET scan results are highly associated with subsequent h

182 rate of change of glucose metabolism on FDG PET scan results.

183 In vivo PET scans revealed an overt age-dependent elevation in w

184 A positron emission tomography (PET) scan revealed no evidence of nodal or distant metas

185 (71.8 +/- 7.94 y old) underwent (11)C-PBR28 PET scanning; rs6971 genotype was imputed after genomewi

186 onstrate the medical necessity of an amyloid PET scan; second, identifying a specific subset of indiv

187 Participants underwent a dynamic PET scanning session with bolus injection of [(11)C]DAA1

188 eek prior to a positron emission tomography (PET) scan session, during which the subject's head was s

189 of the CSF Abeta1-42 samples and florbetapir-PET scans showed a nonlinear association (R2 = 0.48-0.66

190 f levels; and different pipelines to process PET scans showed correlated but not identical results.

191 vorable subgroup, 85.8% had a negative early PET scan (standard arm, one event v experimental arm, ni

192 vorable subgroup, 74.8% had a negative early PET scan (standard arm, seven events v experimental arm,

193 ET/CT imaging was obtained with 2 successive PET scans starting at 2 h after injection.

194 During the first 3 min of a 5-min PET scan, the respiration-induced tissue deformation in

195 After the PET scans, the heroin-dependent subjects performed heroi

196 n the satiated state) and blood draws during PET scanning to determine TSPO affinity genotype and pla

197 human subjects that requires only 90 min of PET scanning to estimate high-affinity alpha4beta2-nAChR

198 lue of BP(ND) and it requires only 90 min of PET scanning to produce estimates of V(T) and BP(ND) in

199 and 10 controls also underwent [(11)C]NNC112 PET scans to measure dopamine D1-type receptor availabil

200 so completed a positron emission tomography (PET) scan to quantify DRN 5-HT1A availability using [(11

201 A single pig with bacterial abscesses was PET-scanned to explore (11)C-donepezil uptake in infecti

202 Furthermore, in rCBV maps and in (18)F-FET PET scans, tumor volumes, their spatial congruence, and

203 Longitudinal PET scans unveiled a lasting and prominent (89)Zr-Df-ALT

204 In NSCLC, baseline (18)F-FDG PET scan uptake showing abnormal texture as measured by

205 ment the region corresponding to BM from the PET scan using algorithms developed in-house, allowing f

206 The quality of the corrected PET scan using our pseudo-CT volume is comparable to hav

207 patients with MDD (HDRS-24 = 24.8) underwent PET scanning using (11)C-DASB.

208 During a 6-y period, 120 PET scans using (18)F-FDG were obtained for 70 AE patien

209 phosphate to induce AAA and underwent weekly PET scans using (64)Cu-NOTA-TRC105-Fab.

210 reward-related questionnaires and underwent PET scans using the D2R-selective and nondisplaceable ra

211 of [(11)C]IMA107 were generated from dynamic PET scans using the simplified reference tissue model wi

212 nce of a larger dynamic range of florbetapir-PET scan values in the higher range compared with the CS

213 (89)Zr-bevacizumab PET scans visualized 125 evaluable tumor lesions in 22 p

214 risk of hospice claims within 180 d of a NaF PET scan was 2.0-7.5 times higher for patients with evid

215 retest variability of (18)F-mefway, a second PET scan was acquired at least 2 wk later for 4 subjects

216 A dynamic PET scan was acquired for 90 s with the brain in the fie

217 The effective dose of the PET scan was estimated by multiplying fludeoxyglucose F1

218 Frequent uncertainty about the need for a PET scan was indicated by 62.3% of the respondents.

219 In 4 patients, an additional PET scan was obtained on day 2 after injection.

220 A PET scan was performed after two initial cycles of doxor

221 An additional PET scan was performed to calculate test-retest reproduc

222 eded, and no treatment adaptation on interim PET scanning was allowed.

223 to tumor identification from a conventional PET scan, we demonstrate the medical utility of our appr

224 es without prior local therapy and (18)F-FET PET scanning were retrospectively identified in 2 center

225 es without prior local therapy and (18)F-FET PET scanning were retrospectively identified in 2 center

226 PET scans were acquired 1 h after injection of 202 MBq (

227 Small-animal PET scans were acquired at 0.5, 1, and 2 h after injecti

228 f 193-232 MBq of (64)Cu-DOTATATE, whole-body PET scans were acquired at 1 h (n = 14), 3 h (n = 12), a

229 Immuno-PET scans were acquired at 30 min and 24 h after injecti

230 [(18)F]FDG-PET scans were acquired at baseline, week 1, and week 8.

231 was injected via the tail vein, and dynamic PET scans were acquired for 90 min, followed by gamma-co

232 (18)F-FDG PET scans were acquired in 8 healthy macaques and 8 maca

233 Pre- and posttreatment PET scans were acquired in protocols compliant with the

234 Non-invasive PET scans were acquired in tumor-bearing mice injected w

235 ion of 37 MBq (5 mg) of (89)Zr-fresolimumab, PET scans were acquired on day 2 or day 4 after tracer i

236 Double baseline (18)F-FDG PET scans were acquired within 4 d of each other for 16

237 The PET scans were analyzed to determine the radiotracer upt

238 The PET scans were analyzed to determine the radiotracer upt

239 PET scans were assessed at 6 time points, up to 110 min

240 ls in 1 transversal slice (SUVmax(9)) of the PET scans were calculated, as well as PET-segmented gros

241 PET scans were classified as positive if tumors identifi

242 18)F-FMZ PET and static interictal (18)F-FDG PET scans were compared in healthy controls (n = 17 for

243 PET scans were done under conditions of suppressed and s

244 Preoperative MR imaging and (68)Ga-DOTATATE PET scans were fused and used for a spatially precise ne

245 PET scans were fused with routine MRI of the central ner

246 Seventy (18)F-FDG PET scans were obtained for 63 GIST patients to evaluate

247 Forty-two (11)C-dLop PET scans were obtained from 37 healthy volunteers.

248 (18)F-FDG and (18)F-FLT PET scans were obtained in 17 patients with FL and 9 pat

249 MBq/kg) rest and pharmacologic stress (82)Rb PET scans were obtained in 25 patients at each site.

250 Two (test-retest) dynamic (11)C-laniquidar PET scans were obtained in 8 healthy subjects.

251 Both dynamic and static PET scans were obtained in a mouse inflammation model in

252 Twenty-two (11)C-AMT PET scans were obtained in adult patients who presented

253 (11)C-DED, (11)C-PiB, and (18)F-FDG dynamic PET scans were obtained in age-matched groups comprising

254 Three small-animal PET scans were obtained over a 4-mo study period.

255 Subsequently, PET scans were obtained when clinical findings or contra

256 Two [(11)C]ABP688 PET scans were performed in 10 healthy nonsmoking human

257 One-hour dynamic PET scans were performed on nude mice bearing subcutaneo

258 an volunteers (34 +/- 13 years old); the two PET scans were performed on the same day-before (scan 1)

259 Initially, MR imaging and PET scans were performed, and diagnosis was confirmed on

260 All PET scans were read by two blinded, independent reviewer

261 Coronary (68)Ga-DOTATATE PET scans were readable in all patients.

262 Quantitative whole-body PET scans were recorded to measure the kinetics for 14 o

263 (18)F-FDG PET scans were selected and grouped according to 3 prepa

264 Dynamic rest and stress (82)Rb PET scans were selected in 30 sequential patient studies

265 The numbers of lesions on FDG and FDHT PET scans were significantly associated with overall sur

266 In addition, the (18)F-FDG PET scans were visually assessed to determine whether th

267 ven whole-body positron emission tomography (PET) scans were performed 5, 10, 20, 30, 45, 150, and 24

268 -(R)-rolipram positron emission tomographic (PET) scans were performed in 44 unmedicated patients dur

269 FLT, no definite uptake could be observed on PET scans, whereas autoradiography showed slight radiotr

270 A dynamic PET scan with a field of view covering target tissues of

271 A 90-min dynamic PET scan with arterial blood sampling and metabolite ana

272 Methods: A 90-min dynamic PET scan with arterial blood sampling and metabolite ana

273 fter tumor inoculation, a dynamic (18)F-FHNP PET scan with arterial blood sampling was acquired from

274 , a dynamic (11)C-PBR28 or (R)-(11)C-PK11195 PET scan with arterial blood sampling was obtained.

275 n was followed by a 60-min dynamic (18)F-FDG PET scan with cardiac and respiratory gating.

276 agnetic resonance imaging scan and a resting PET scan with the CB1 receptor antagonist radiotracer [(

277 After a baseline PET scan with the D2/3 ligand [(18)F]fallypride, rats re

278 After a baseline PET scan with the D2/3 ligand [(18)F]fallypride, rats we

279 All participants had a baseline PET scan with the P-glycoprotein substrate (R)-[(11)C]ve

280 complex logistics of combining a whole-body PET scan with whole-body or organ-specific MR imaging.

281 s, and 32 healthy control subjects underwent PET scanning with [(11)C]DASB to quantify in vivo region

282 tor protein (TSPO) binding status, underwent PET scanning with TSPO radioligands ((11)C-PBR28 or (18)

283 Three small-animal PET scans with (18)F-FDG were obtained: on days 0, 7, an

284 Dynamic PET scans with (18)F-FETrp and (11)C-AMT were obtained f

285 very for 5 to 7 days before one hour dynamic PET scans with [(11)C]PK11195 and/or [(18)F]DPA-714 unde

286 armacotherapy completed both [11C]WAY-100635 PET scans with a metabolite-corrected arterial input fun

287 ed-affinity binders) underwent (18)F-DPA-714 PET scans with arterial blood sampling and metabolite an

288 Small-animal PET scans with arterial blood sampling were obtained for

289 men and 5 women) underwent 2 separate 90-min PET scans with arterial input function and plasma free f

290 r the rs6971 polymorphism, underwent 120-min PET scans with arterial sampling after a bolus injection

291 subsequent dynamic (15)O-H2O and (18)F-FAZA PET scans with arterial sampling.

292 Ninety-minute dynamic (18)F-DPA-714 PET scans with full arterial sampling from 6 healthy sub

293 Rats and mice underwent 4 PET scans with increasing doses of the unlabeled ligand

294 We performed PET scans with the ABCB1 substrate (R)-(11)C-verapamil o

295 Methods: We performed PET scans with the ABCB1 substrate (R)-(11)C-verapamil o

296 kers underwent positron emission tomography (PET) scanning with the radiotracer 2-FA (for labeling al

297 g (MRI) scans, positron emission tomography (PET) scans with carbon 11-labeled Pittsburgh Compound B

298 One hundred patients were PET-scanned with both (18)F-FLT and (18)F-FDG within the

299 were subjected to a series of 10 whole-body PET scans within approximately 70 min.

300 In the 23 paired PET scans, worsening cardiac denervation (global diff-SE